导师风采
应建明
个人信息
Personal Information
- 性别：男
- 导师类型：博士生导师
- 职称：主任医师
- 该职称任职时间：9
联系方式
Contact Information
- 所属院系：肿瘤医院
- 所属专业：临床病理
- 邮箱 : jmying@cicams.ac.cn
- 工作电话 : 010-87787515
个人简介
Personal Profile
1. 教育经历： 博士，2004年09月-2007年07月，中国，香港中文大学医学院，医学 硕士，1998年09月-2000年07月，中国，北京大学医学部，病理学 学士，1993年09月-1998年07月，中国，北京医科大学，基础医学 2. 工作经历： 住院医师，2000年08月-2008年04月，中国医学科学院肿瘤医院 主治医师，2008年05月-2010年06月，中国医学科学院肿瘤医院 副主任医师，2010月07月-2015年06月，中国医学科学院肿瘤医院 主任医师，2015年07月至今，中国医学科学院肿瘤医院
团队简介
Team Profile
应建明是国家临床病理重点专科、国家首批高通量测序临床应用试点单位（肿瘤）、国家病理质控中心示范实验室负责人和分子肿瘤学国家重点实验室PI。团队在分子新技术开发、临床应用及肿瘤病理转化研究领域具有丰富经验，人员梯队合理。团队依托国家重点研发计划等国家级项目，取得了一系列创新成果，发表论文200余篇，含Annals of Oncology，Journal of Thoracic Oncology等顶尖期刊。获北京市科学技术进步奖二等奖及中国抗癌协会科技奖二等奖；承担国家重点研发计划、国自然面上、国自然青年、省部级及局级课题多项；授权国家发明专利6项，软件著作权1项。
- 研究方向Research Directions
肿瘤病理,分子病理
- 在校研究生Current Graduate Students
硕士研究生 0 名，博士研究生 8 名
- 科研项目Research Projects
| # | 项目名称 | 起止日期 | 金额 | 项目类型 | 本人角色 |
|---|---|---|---|---|---|
| 1 | 肺癌新辅助免疫治疗疗效预测综合评价体系的建立和应用 | 2022-01-01 —— | 55.0 | ||
| 2 | 基于组织病理风险因素及血液CtDNA监测用于肺癌术后预后评估体系的建立及应用 | 2022-10-01 —— 2024-09-30 | 41.6 | ||
| 3 | 恶性肿瘤早期诊断及筛查体外诊断试剂临床试验示范体系建立和应用 | 2022-11-01 —— | 370.0 |
- 发表论文Papers
| # | 论文题目 | 期刊名称 | 发表年份 | 论文署名 |
|---|---|---|---|---|
| 1 | A CT-based radiomics approach to predict intra-tumoral tertiary lymphoid structures and recurrence of intrahepatic cholangiocarcinoma | Insights into Imaging | 2023-10 | 通讯作者 |
| 2 | ALK Rearrangement–Positive Pancreatic Cancer with Brain Metastasis Has Remarkable Response to ALK Inhibitors: A Case Report | Frontiers in Oncology | 2021-09 | 通讯作者 |
| 3 | Assessment of HER2 status in extramammary Paget disease and its implication for disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate therapy | Frontiers of Medicine | 2024-05 | 通讯作者 |
| 4 | Association between MRI radiomics and intra-tumoral tertiary lymphoid structures in intrahepatic cholangiocarcinoma and its prognostic significance | JOURNAL OF MAGNETIC RESONANCE IMAGING | 2023-11 | 通讯作者 |
| 5 | CD74/SLC34A2-ROS1 Fusion Variants Involving the Transmembrane Region Predict Poor Response to Crizotinib in NSCLC Independent of TP53 Mutations | Journal of Thoracic Oncology | 2024-04 | 通讯作者 |
| 6 | Classic SRY-box protein SOX7 functions as a tumor suppressor regulating WNT signaling and is methylated in renal cell carcinoma | FASEB JOURNAL | 2019-01 | 通讯作者 |
| 7 | Clinicopathologic characteristics and diagnostic methods of RET rearrangement in Chinese non-small cell lung cancer patients | Translational Lung Cancer Research | 2022-04 | 通讯作者 |
| 8 | Clinicopathological correlation with expression of PD-L1 on both tumor cells and tumor-infiltrating immune cells in patients with non-small cell lung cancer | JOURNAL OF IMMUNOTHERAPY | 2019-01 | 通讯作者 |
| 9 | Comprehensive analysis of single-cell and bulk RNA-sequencing data identifies B cell marker genes signature that predicts prognosis and analysis of immune checkpoints expression in head and neck squamous cell carcinoma | Heliyon | 2023-11 | 通讯作者 |
| 10 | Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK‐rearranged non‐small‐cell lung cancer | Cancer Medicine | 2019-03 | 通讯作者 |
| 11 | Concurrent Presence of ALK Rearrangement and MET Mutation in Lung Adenocarcinoma | Journal of Thoracic Oncology | 2019-02 | 通讯作者 |
| 12 | Conjoint Analysis of DNA Methylation for Tumor Differentiation Using Cationic Conjugated Polymers | ACS APP | 2020-12 | 通讯作者 |
| 13 | Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants | Cancer Medicine | 2020-05 | 通讯作者 |
| 14 | Cytoplasmic MSH2 Related to Genomic Deletions in the MSH2/EPCAM Genes in Colorectal Cancer Patients With Suspected Lynch Syndrome | Frontiers in Oncology | 2021-05 | 通讯作者 |
| 15 | Deep learning on tertiary lymphoid structures in hematoxylin-eosin predicts cancer prognosis and immunotherapy response | npj Precision Oncology | 2024-03 | 通讯作者 |
| 16 | Developing an efective quality evaluation strategy of next‑generation sequencing for accurate detecting non‑small cell lung cancer samples with variable characteristics: a real‑world clinical practice | JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | 2023-07 | 通讯作者 |
| 17 | Development and validation of nomograms for predicting axillary non-SLN metastases in breast cancer patients: A retrospective analysis | Frontiers in Oncology | 2023-03 | 通讯作者 |
| 18 | Different pathologic responses to neoadjuvant anti-PD-1 in primary squamous lung cancer and regional lymph nodes | npj Precision Oncology | 2020-12 | 通讯作者 |
| 19 | Disease monitoring of epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer patients treated with tyrosine kinase inhibitors via EGFR status in circulating tumor DNA | Thoracic Cancer | 2022-06 | 通讯作者 |
| 20 | Distinct clinical phenotype and genetic testing strategy for Lynch syndrome in China based on a large colorectal cancer cohort | INTERNATIONAL JOURNAL OF CANCER | 2020-06 | 通讯作者 |
| 21 | DLBCL with amplification of JAK2/PD-L2 exhibits PMBCL-like CNA pattern and worse clinical outcome resembling those with MYD88 L265P mutation | BMC CANCER | 2020-08 | 通讯作者 |
| 22 | Establishment and validation of a multigene model to predict the risk of relapse in HR-positive early-stage Chinese breast cancer patients | CHINESE MEDICAL JOURNAL | 2023-01 | 通讯作者 |
| 23 | Genomic profile and immune microenvironment in patients with relapsed stage IA lung adenocarcinoma | Translational Oncology | 2020-11 | 通讯作者 |
| 24 | HBV integrations reshaping genomic structures promote hepatocellular carcinoma | GUT | 2024-02 | 第一作者 |
| 25 | Heterogeneous Response to First-generation Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancers with Different EGFR Exon 19 Mutations | Targeted Oncology | 2020-05 | 通讯作者 |
| 26 | High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes | Thoracic Cancer | 2020-07 | 通讯作者 |
| 27 | Identification of DNA methylation biomarkers for risk of liver metastasis in early‑stage colorectal cancer | Clinical Epigenetics | 2021-06 | 通讯作者 |
| 28 | Immune-related histologic phenotype in pretreatment tumour biopsy predicts the efcacy of neoadjuvant anti-PD-1 treatment in squamous lung cancer | BMC Medicine | 2022-10 | 通讯作者 |
| 29 | Intergenic Breakpoints Identified by DNA Sequencing Confound Targetable Kinase Fusion Detection in NSCLC | Journal of Thoracic Oncology | 2020-06 | 通讯作者 |
| 30 | Major challenges in accurate mutation detection of multifocal lung adenocarcinoma by next-generation sequencing | CANCER BIOLOGY & THERAPY | 2020-02 | 通讯作者 |
| 31 | Multi-dimensional characterization of immunological profiles in small cell lung cancer uncovers clinically relevant immune subtypes with distinct prognoses and therapeutic vulnerabilities | PHARMACOLOGICAL RESEARCH | 2023-06 | 通讯作者 |
| 32 | Mutation Landscape of Homologous Recombination Repair Genes in Epithelial Ovarian Cancer in China and Its Relationship With Clinicopathlological Characteristics | Frontiers in Oncology | 2022-02 | 通讯作者 |
| 33 | Necrosis is not the main part of immune-related pathologic response to neoadjuvant immunotherapy in squamous lung cancer | Journal of Thoracic Oncology | 2020-12 | 通讯作者 |
| 34 | Patient Assessment and Therapy Planning Based on Homologous Recombination Repair Deficiency | GENOMICS PROTEOMICS & BIOINFORMATICS | 2023-02 | 通讯作者 |
| 35 | PDCD6 cooperates with C-Raf to facilitate colorectal cancer progression via Raf/MEK/ ERK activation | JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH | 2020-08 | 通讯作者 |
| 36 | PD-L1 expression in recurrent or metastatic head and neck squamous cell carcinoma in China (EXCEED study): a multicentre retrospective study | JOURNAL OF CLINICAL PATHOLOGY | 2023-11 | 通讯作者 |
| 37 | Potential unreliability of ALK variant allele frequency in the efficacy prediction of targeted therapy in NSCLC | Frontiers of Medicine | 2023-06 | 通讯作者 |
| 38 | Potential Unreliability of Uncommon ALK, ROS1,and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC | Journal of Thoracic Oncology | 2021-03 | 通讯作者 |
| 39 | Prevalence and characteristics of PIK3CA mutation in mismatch repair-deficient colorectal cancer | Journal of Cancer | 2020-04 | 通讯作者 |
| 40 | Prevalence and Prognostic Relevance of Homologous Recombination Repair Gene Mutations in Uterine Serous Carcinoma | Cells | 2022-11 | 通讯作者 |
| 41 | Proficiency testing of diagnosis in histopathology and immunohistochemistry of breast pathology in China: results from a pilot work of National Single Disease Quality Control Program for breast cancer | BMC CANCER | 2024-01 | 通讯作者 |
| 42 | Prognostic significance of tumor-infiltrating lymphocytes in premenopausal, luminal breast cancer treated with adjuvant endocrine therapy | American Journal of Translational Research | 2021-11 | 通讯作者 |
| 43 | Programmable endonuclease combined with isothermal polymerase amplification to selectively enrich for rare mutant allele fractions | CHINESE CHEMICAL LETTERS | 2022-06 | 通讯作者 |
| 44 | Reliability analysis of exonic‑breakpoint fusions identified by DNA sequencing for predicting the efficacy of targeted therapy in non‑small cell lung cancer | BMC Medicine | 2022-05 | 通讯作者 |
| 45 | RING finger 138 deregulation distorts NF-кB signaling and facilities colitis switch to aggressive malignancy | Signal Transduction and Targeted Therapy | 2022-06 | 第一作者 |
| 46 | Safety, Antitumor Activity, and Pharmacokinetics of Toripalimab, a Programmed Cell Death 1 Inhibitor, in Patients With Advanced Non–Small Cell Lung Cancer A Phase 1 Trial | JAMA Network Open | 2020-10 | 第一作者 |
| 47 | Sclerosing thymoma: a case report and literature review | Translational Cancer Research | 2020-02 | 通讯作者 |
| 48 | The Distinct Performances of Ultrasound, Mammograms, and MRI in Detecting Breast Cancer in Patients With Germline Pathogenic Variants in Cancer Predisposition Genes | Frontiers in Oncology | 2021-07 | 通讯作者 |
| 49 | The prognostic value of a Methylome-based Malignancy Density Scoring System to predict recurrence risk in early-stage Lung Adenocarcinoma | Theranostics | 2020-06 | 通讯作者 |
| 50 | The prognostic value of tumour-infiltrating lymphocytes, programmed cell death protein-1 and programmed cell death ligand-1 in Stage I-III triple-negative breast cancer | BRITISH JOURNAL OF CANCER | 2023-06 | 通讯作者 |
| 51 | Transdifferentiation of tumor infiltrating innate lymphoid cells during progression of colorectal cancer | CELL RESEARCH | 2020-07 | 通讯作者 |
| 52 | Tumor budding and tumor-infiltrating lymphocytes can predict prognosis in pT1b esophageal squamous cell carcinoma | Thoracic Cancer | 2023-09 | 通讯作者 |
| 53 | Ultra-rapid IdyllaTM EGFR mutation screening followed by next-generation sequencing: an integrated solution to molecular diagnosis of non-small cell lung cancer | Frontiers in Oncology | 2023-03 | 通讯作者 |
| 54 | Using immunovascular characteristics to predict very early recurrence and prognosis of resectable intrahepatic cholangiocarcinoma | BMC CANCER | 2023-10 | 通讯作者 |
| 55 | Variation of Programmed Death Ligand 1 Expression After Platinum-based Neoadjuvant Chemotherapy in Lung Cancer | JOURNAL OF IMMUNOTHERAPY | 2019-04 | 通讯作者 |
| 56 | A Case Report of ZC3H7B-BCOR High-grade Endometrial Stromal Sarcoma Expressing CD117 and DOG1: A Molecularly Confirmed Diagnostic Pitfall | Journal of Clinical and Translational Pathology | 2024-03 | 通讯作者 |
| 57 | Assessment of HER2 status in urothelial cancer and its correlation with efficacy of HER2-targeting antibody-drug conjugate therapy | Journal of the National Cancer Center | 2023-06 | 通讯作者 |
| 58 | Comparative Epigenetic Profiling Reveals Distinct Features of Mucosal Melanomas Associated with Immune Cell Infiltration and Their Clinical Implications | Cancer Research Communications | 2024-05 | 通讯作者 |
| 59 | Detection of MET Polysomy by Next-generation Sequencing and Its Clinical Relevance for MET Inhibitors | cancer research communications | 2023-04 | 通讯作者 |
| 60 | Guidelines for clinical practice of ALK fusion detection in non-small-cell lung cancer: a proposal from the Chinese RATICAL study group | Journal of the National Cancer Center | 2021-07 | 通讯作者 |
| 61 | The Reproducibility of Histopathologic Assessments of Programmed Cell Death-Ligand 1 Using Companion Diagnostics in NSCLC | JTO Clinical and Research Reports | 2021-02 | 通讯作者 |
| 62 | Metastatic NSCLCs With Limited Tissues: How to Effectively Identify Driver Alterations to Guide Targeted Therapy in Chinese Patients | JTO Clinical and Research Reports | 2021-05 | 通讯作者 |
| 63 | Trends in Molecular Testing of Lung Cancer in Mainland People’s Republic of China Over the Decade 2010 to 2019 | JTO clinical and research reports | 2021-03 | 通讯作者 |
| 64 | 肿瘤微环境在三阴性乳腺癌免疫治疗中的研究进展 | 首都医科大学学报 | 2023-10 | 通讯作者 |
| 65 | FGFR基因变异及FGFR受体抑制剂的研究进展 | 中国肿瘤 | 2023-04 | 通讯作者 |
| 66 | KRAS G12C 突变在消化系统恶性肿瘤中的分子特点 | 肝癌电子杂志 | 2024-03 | 通讯作者 |
| 67 | T1N3期和T3N0期乳腺癌组织中M1型巨噬细胞的浸润及意义 | 中华肿瘤杂志 | 2022-11 | 通讯作者 |
| 68 | 鼻咽部EB病毒阳性大细胞神经内分泌癌一例 | 中华病理学杂志 | 2021-05 | 通讯作者 |
| 69 | 雌激素受体阴性孕激素受体阳性乳腺癌研究进展 | 中华内分泌外科杂志 | 2021-02 | 通讯作者 |
| 70 | 非小细胞肺癌MET免疫组织化学检测 和判读标准中国专家共识（2023版） | 中华病理学杂志 | 2023-11 | 通讯作者 |
| 71 | 非小细胞肺癌分子病理检测临床实践指南（2021版） | 中华病理学杂志 | 2021-04 | 第一作者 |
| 72 | 非小细胞肺癌融合基因检测临床实践中国专家共识 | 中华病理学杂志 | 2023-06 | 通讯作者 |
| 73 | 非小细胞肺癌新辅助治疗疗效病理评估专家共识 | 中华病理学杂志 | 2021-09 | 通讯作者 |
| 74 | 复合型环保试剂超声组织快速处理技术对肿瘤活检标本蛋白及分子检测的影响 | 中华病理学杂志 | 2019-02 | 通讯作者 |
| 75 | 黑色素瘤病理诊断临床实践指南（2021版） | 中华病理学杂志 | 2021-06 | 第一作者 |
| 76 | 基于二代测序技术比较结直肠癌原发灶与同时或异时性肝转移灶基因突变状态的异同 | 肝癌电子杂志 | 2020-03 | 通讯作者 |
| 77 | 甲状腺滤泡性肿瘤基因突变及其临床病理特征分析 | 中华肿瘤杂志 | 2019-08 | 通讯作者 |
| 78 | 弥漫性大B 细胞淋巴瘤中丝裂原活化蛋白激酶10基因甲基化的临床意义 | 中国肿瘤临床与康复 | 2019-04 | 通讯作者 |
| 79 | 实体肿瘤PD‐L1免疫组织化学检测 专家共识（2021版） | 中华病理学杂志 | 2021-07 | 第一作者 |
| 80 | 院内开展实验室自建肿瘤全景变异分析性能确认的中国专家共识 | 中华肿瘤杂志 | 2024-04 | 通讯作者 |
| 81 | 中国非小细胞肺癌ALK检测临床实践专家共识 | 中华病理学杂志 | 2019-12 | 通讯作者 |
| 82 | 中国非小细胞肺癌PD-L1表达检测临床病理专家共识 | 中华肿瘤杂志 | 2020-06 | 通讯作者 |
| 83 | 中国非小细胞肺癌RET基因融合临床检测专家共识 | 中华病理学杂志 | 2021-06 | 通讯作者 |
| 84 | 中国非小细胞肺癌表皮生长因子受体20号外显子插入突变检测临床实践专家共识（2024版） | 中华肿瘤杂志 | 2024-03 | 通讯作者 |
| 85 | 中国肺腺癌ALK Ventana-D5F3免疫组织化学检测结果判读一致性质控研究 | 中华病理学杂志 | 2019-12 | 通讯作者 |
| 86 | 中国尿路上皮癌HER2检测临床病理专家共识 | 中华肿瘤杂志 | 2021-10 | 通讯作者 |
| 87 | 肿瘤组织病理诊断的发展现状、 机遇与挑战 | 中华病理学杂志 | 2020-11 | 第一作者 |
| 88 | 肿瘤突变负荷检测及临床应用中国专家共识（2020 年版） | 中国癌症防治杂志 | 2020-10 | 第一作者 |
- 科研获奖Research Awards
| # | 获奖证书编号 | 奖项名称 | 获奖级别 | 获奖类别 | 获奖等级 | 获奖日期 | 颁奖单位 | 本单位是否为第一完成单位 | 完成单位排名 | 本人排序 | 备注 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 无证书 | 北京市科学技术奖 | 省部级 | 其他省部级奖励 | 二等奖 | 2023-06-13 | 北京市奖励委员会 | 是 | 1 | 1 | |
| 2 | 201803003P0806 | 华夏医学科技奖 | 省部级 | 其他省部级奖励 | 三等奖 | 2018-11-10 | 中国医疗保健国际交流促进会 | 1 | 6 |
- 研究成果Research Findings
| # | 成果类型 | 项目/专利/新品种名称 |
|---|---|---|
| 1 | 作为主创人员获得授权的发明专利和新品种 | 一种非小细胞肺癌免疫治疗疗效的预测模型的训练方法以及预测装置 |
| 2 | 作为主创人员获得授权的发明专利和新品种 | 一种用于预测肿瘤突变负荷的核酸组合物及其方法和设备 |
| 3 | 出版高水平专著 | 肿瘤术中病理诊断图谱及解析 |
| 4 | 出版高水平专著 | 临床病理学典型案例诊断图谱 |
| 5 | 出版高水平专著 | 外科病理鉴别诊断图谱：乳腺 |
| 6 | 获得省部级及以上科研奖励 | 2022 肿瘤分子病理关键技术创新与推广应用（北京市科技奖二等奖） |